Your browser doesn't support javascript.
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.
Onesti, Concetta Elisa; Tagliamento, Marco; Curigliano, Giuseppe; Harbeck, Nadia; Bartsch, Rupert; Wildiers, Hans; Tjan-Heijnen, Vivianne; Martin, Miguel; Rottey, Sylvie; Generali, Daniele; Campone, Mario; Cristofanilli, Massimo; Pusztai, Lajos; Peeters, Marc; Berchem, Guy; Cortes, Javier; Ruhstaller, Thomas; Ciruelos, Eva; Rugo, Hope S; Jerusalem, Guy.
  • Onesti CE; Medical Oncology Department, CHU Sart Tilman Liege and Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium.
  • Tagliamento M; Oncology Department, University of Genova and IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Curigliano G; Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS and University of Milan, Milan, Italy.
  • Harbeck N; Breast Center, Department OB&GYN and CCCLMU, LMU University Hospital, Munich, Germany.
  • Bartsch R; Department of Medicine I, Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, Wien, Austria.
  • Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Tjan-Heijnen V; Medical Oncology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands.
  • Martin M; Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense, Madrid, Spain.
  • Rottey S; Department of Medical Oncology, UZ Gent, Gent, Belgium.
  • Generali D; UO Patologia Mammaria e Ricerca Traslazionale-Breast Unit, Azienda Socio-Sanitaria, Territoriale di Cremona and University of Trieste, Cremona, Italy.
  • Campone M; Medical Oncology, Institut de Cancérologie de l'Ouest-Pays de la Loire, Saint-Herblain, France.
  • Cristofanilli M; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.
  • Pusztai L; Yale Cancer Center, Yale School of Medicine, New Haven, CT.
  • Peeters M; Oncology Department, University Hospital Antwerp (UZA), Edegem, Belgium.
  • Berchem G; Hemato-Oncology Department, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
  • Cortes J; Oncology Department, IOB Institute of Oncology, Quiron Group, Madrid, Barcelona, Spain.
  • Ruhstaller T; Vall d'Hebron Institute of Oncology (VHIO), Centro Cellex, Carrer de Natzaret, Barcelona, Spain.
  • Ciruelos E; Medical Oncology, Breast Center Eastern Switzerland, St Gallen, Switzerland.
  • Rugo HS; University of Basel, St Gallen, Switzerland.
  • Jerusalem G; Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
JCO Glob Oncol ; 7: 162-172, 2021 02.
Article in English | MEDLINE | ID: covidwho-1060222
ABSTRACT

PURPOSE:

The COVID-19 pandemic has affected healthcare systems globally, leading to reorganization of medical activities. We performed an international survey aimed to investigate the medium- and long-term impact on oncology units. MATERIALS AND

METHODS:

An 82-item survey was distributed from June 17 to July 14, 2020 among medical oncologists worldwide.

RESULTS:

One hundred nine medical oncologists from 18 countries in Europe (n = 93), United States (n = 5), and Latin America (n = 11) answered the survey. A systematic tracing of COVID-19-positive patients was continued in the postacute phase by 77.1% of the centers; 64.2% of the respondents participated in a local registry and 56% in international or national registries of infected patients. Treatment adaptations were introduced, and surgery was the most affected modality being delayed or canceled in more than 10% of patients in 34% of the centers, whereas early cessation of palliative treatment was reported in 32.1% of the centers; 64.2% of respondents reported paying attention to avoid undertreatments. The use of telemedicine has been largely increased. Similarly, virtual tools are increasingly used particularly for medical education and international or national or multidisciplinary meetings. 60.6% of the participants reduced clinical activity, and 28.4% compensated by increasing their research activity. Significant reduction of clinical trial activities is expected in 37% of centers this year. The well-being of healthcare staff would not recover by the end of the year according to 18% of the participants.

CONCLUSION:

The COVID-19 outbreak has had a major impact on oncologic activity, which will persist in the future, irrespective of geographical areas.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 / Medical Oncology / Neoplasms Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Systematic review/Meta Analysis Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America / Europa Language: English Journal: JCO Glob Oncol Year: 2021 Document Type: Article Affiliation country: Go.20.00589

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 / Medical Oncology / Neoplasms Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Systematic review/Meta Analysis Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America / Europa Language: English Journal: JCO Glob Oncol Year: 2021 Document Type: Article Affiliation country: Go.20.00589